The Value of Molecular Imaging for Prostate Cancer
Molecular imaging without compromise

Clinical molecular imaging prostate image
The Value of Molecular Imaging for Prostate Cancer
Ihr Kontakt zu uns

Prostate cancer facts and figures

Case studies

Detection of Bladder Invasion and Pelvic Lymph Node Metastases in a Patient with Primary Prostate Cancer

A 62-year-old man with primary prostate cancer, diagnosed on clinical examination and transrectal ultrasound, underwent 68Ga PSMA5 PET/CT for initial staging. The PET/CT study was performed on Biograph Vision™.

Detection of Solitary Pelvic Lymph Node Metastasis in a Patient with Primary Prostate Cancer

A 78-year-old male with a medical history of lower urinary tract symptoms, referred for primary staging of his newly-diagnosed Gleason 3+4 prostate cancer, underwent a 68Ga PSMA5 PET/CT for initial staging on Biograph Vision™.

Differentiation of a rib benign lesion from a metastasis using xSPECT Quant

A 58-year-old patient with prostatic hypertrophy underwent a prostatectomy, which led to an incidental discovery of adenocarcinoma of the prostate. After initial planar acquisitions were conducted, a subsequent SPECT/CT examination using xSPECT Bone™ and xSPECT Quant™ was administered for the thorax.

Verwandte Produkte, Dienstleistungen und Ressourcen

1Siegel, R., Miller, K. & Jemal, A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians 67, 7–30 (2017).

2Torre, LA., et al. Global cancer statistics, 2012, CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262.

3The tracer mentioned is a research radiopharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in all countries.

4Please see indication and important safety information at

568Ga PSMA referenced herein is (are) not currently recognized by the US FDA as being safe and effective, and Siemens does not make any claims regarding its use.

Image data courtesy of WVU Medical Center, Morgantown, West Virginia, USA.